Brief: Briacell Therapeutics In Discussions With FDA To Advance To Its Pivotal Study, Move Forward With Registration Study Along Path To FDA Approval
15/11/2022 13:39
Nov 15 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL THERAPEUTICS CORP - IN DISCUSSIONS WITH FDA TO
ADVANCE
TO ITS PIVOTAL STUDY, MOVE FORWARD WITH REGISTRATION STUDY ALONG
PATH TO FDA APPROVAL
Source text for Eikon: ID:nGNX5z1v1b
Further company coverage: BCT.TO
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study